Valuation: DiaMedica Therapeutics Inc.

Market Cap 500M 360M 311M 292M 266M 34.45B 508M 3.43B 1.34B 17.25B 1.35B 1.32B 57.32B P/E 2026 *
-8.22x
P/E 2027 * -8.27x
Enterprise Value 500M 360M 311M 292M 266M 34.45B 508M 3.43B 1.34B 17.25B 1.35B 1.32B 57.32B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
56.63%
Yield 2026 *
-
Yield 2027 * -
1 day-1.04%
1 week-1.04%
Current month+5.36%
1 month-12.57%
3 months+10.23%
6 months-21.69%
Current year-16.08%
1 week 6.44
Extreme 6.44
7.17
1 month 6.25
Extreme 6.25
7.51
Current year 5.24
Extreme 5.245
9.04
1 year 5.14
Extreme 5.14
10.42
3 years 1.94
Extreme 1.9382
10.42
5 years 1.12
Extreme 1.12
10.42
10 years 1.12
Extreme 1.12
13.77
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2010
Director of Finance/CFO 60 01/04/2018
Chief Tech/Sci/R&D Officer 60 11/08/2025
Director TitleAgeSince
Director/Board Member 70 10/08/2010
Chairman 54 01/04/2008
Chairman 60 01/01/2025
Date Insider Type Main position Quantity % Market Cap.
10/8/26 Free

Chief Executive Officer

60,200 0.1117%
1/6/26 Free

Chief Executive Officer

380,000 -
1/6/26 Option

Chief Technology Officer

67,500 0.1253%
Change 5-day change 1-year change 3-year change Capi.($)
-1.04%-1.04%+10.78%+125.30% 360M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.42%+1.65%+48.56%+197.57% 26.4B
Weighted average by Cap. -1.09%+0.55%+50.18%+164.94%

Financials

2026 *2027 *
Net sales - -
Net income -62.74M -45.21M -39.05M -36.69M -33.37M -4.32B -63.77M -430M -168M -2.16B -170M -166M -7.19B -71.13M -51.25M -44.27M -41.6M -37.83M -4.9B -72.3M -487M -191M -2.45B -192M -188M -8.16B
Net Debt - -
Logo DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.
Employees
35
Date Price Change Volume
14/08/26 USD 6.680 -1.04% 165,178
13/08/26 USD 6.750 -1.32% 111,874
12/08/26 USD 6.840 -0.44% 140,044
11/08/26 USD 6.870 +3.31% 176,298
10/08/26 USD 6.650 -1.48% 184,605
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.680USD
Average target price
15.50USD
Spread / Average Target
+132.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMAC Stock